Literature DB >> 18000714

Phosphorus-31 two-dimensional chemical shift imaging in the myocardium of patients with late onset of Friedreich ataxia.

Christian Wolf1, Sylvia Boesch, Bernhard Metzler, Helga Weirich-Schwaiger, Thomas Trieb, Michael F H Schocke.   

Abstract

PURPOSE: Friedreich ataxia (FRDA) is characterized by GAA expansions in the intron 1 of the frataxin gene correlating with disease onset and progression as well as cardiac affection. Accordingly, FRDA patients with early disease onset show a clear impairment of mitochondrial function in the myocardium. The purpose of this study was to investigate cardiac function and high-energy phosphate metabolism in FRDA patients with late disease onset. PROCEDURES: Using a 1.5 T magnetic resonance scanner, cardiac phosphorus-31 two-dimensional chemical shift imaging was performed in ten patients (seven male, three female) with a late onset of FRDA and in 35 healthy, male controls. Ejection faction (EF) and interventricular septum thickness (IST) were determined by echocardiography.
RESULTS: The differences in left ventricular phosphocreatine (PCr) to beta-adenosine triphosphate (beta-ATP) ratios between both groups were not significant. FRDA patients had increased ISTs (10.8+/-1.6 vs. 9.7+/-0.9 mm; p=0.048), which correlated significantly with the left ventricular PCr to beta-ATP ratios (r= -0.644; p=0.04), and decreased EFs (52.24+/-7.72% vs. 64.09+/-4.25%; p=0.001) compared to normal controls.
CONCLUSIONS: In contrast to FRDA patients with early disease onset, our patients collective exhibited a normal, probably compensated cardiac mitochondrial function, whereby IST and EF were mildly altered.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18000714     DOI: 10.1007/s11307-007-0119-y

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN: 1536-1632            Impact factor:   3.488


  27 in total

1.  Quantifying in vivo MR spectra with circles.

Authors:  Refaat E Gabr; Ronald Ouwerkerk; Paul A Bottomley
Journal:  J Magn Reson       Date:  2005-12-01       Impact factor: 2.229

2.  Mitochondrial iron detoxification is a primary function of frataxin that limits oxidative damage and preserves cell longevity.

Authors:  Oleksandr Gakh; Sungjo Park; Gang Liu; Lee Macomber; James A Imlay; Gloria C Ferreira; Grazia Isaya
Journal:  Hum Mol Genet       Date:  2005-12-21       Impact factor: 6.150

3.  Myocardial blood flow and oxygen consumption in patients with Friedreich's ataxia prior to the onset of cardiomyopathy.

Authors:  Shawn A Gregory; Calum A MacRae; Kusai Aziz; Katherine B Sims; Jeremy D Schmahmann; Arash Kardan; Alexander M Morss; Patrick T Ellinor; Ahmed Tawakol; Alan J Fischman; Henry Gewirtz
Journal:  Coron Artery Dis       Date:  2007-02       Impact factor: 1.439

4.  Age of onset, sex, and cardiomyopathy as predictors of disability and survival in Friedreich's disease: a retrospective study on 119 patients.

Authors:  G De Michele; F Perrone; A Filla; E Mirante; M Giordano; S De Placido; G Campanella
Journal:  Neurology       Date:  1996-11       Impact factor: 9.910

5.  Cardiac energetics are abnormal in Friedreich ataxia patients in the absence of cardiac dysfunction and hypertrophy: an in vivo 31P magnetic resonance spectroscopy study.

Authors:  R Lodi; B Rajagopalan; A M Blamire; J M Cooper; C H Davies; J L Bradley; P Styles; A H Schapira
Journal:  Cardiovasc Res       Date:  2001-10       Impact factor: 10.787

6.  Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits.

Authors:  H Puccio; D Simon; M Cossée; P Criqui-Filipe; F Tiziano; J Melki; C Hindelang; R Matyas; P Rustin; M Koenig
Journal:  Nat Genet       Date:  2001-02       Impact factor: 38.330

7.  High-energy phosphate metabolism during calf ergometry in patients with isolated aorto-iliac artery stenoses.

Authors:  Michael F H Schocke; Regina Esterhammer; Stephanie Ostermann; Wolfram Santner; Olaf Gorny; Gustav Fraedrich; Werner R Jaschke; Andreas Greiner
Journal:  Invest Radiol       Date:  2006-12       Impact factor: 6.016

8.  Clinical and genetic abnormalities in patients with Friedreich's ataxia.

Authors:  A Dürr; M Cossee; Y Agid; V Campuzano; C Mignard; C Penet; J L Mandel; A Brice; M Koenig
Journal:  N Engl J Med       Date:  1996-10-17       Impact factor: 91.245

9.  Cardiac phosphorus-31 two-dimensional chemical shift imaging in patients with hereditary hemochromatosis.

Authors:  Michael F H Schocke; Heinz Zoller; Wolfgang Vogel; Christian Wolf; Christian Kremser; Peter Steinboeck; Gerhard Poelzl; Otmar Pachinger; Werner R Jaschke; Bernhard Metzler
Journal:  Magn Reson Imaging       Date:  2004-05       Impact factor: 2.546

10.  Cardiac energetics correlates to myocardial hypertrophy in Friedreich's ataxia.

Authors:  Michael Bunse; Nana Bit-Avragim; Axel Riefflin; Andreas Perrot; Oliver Schmidt; Friedmar R Kreuz; Rainer Dietz; Wulf-Ingo Jung; Karl Josef Osterziel
Journal:  Ann Neurol       Date:  2003-01       Impact factor: 10.422

View more
  2 in total

1.  Bioenergetics of the calf muscle in Friedreich ataxia patients measured by 31P-MRS before and after treatment with recombinant human erythropoietin.

Authors:  Wolfgang Nachbauer; Sylvia Boesch; Rainer Schneider; Andreas Eigentler; Julia Wanschitz; Werner Poewe; Michael Schocke
Journal:  PLoS One       Date:  2013-07-29       Impact factor: 3.240

2.  Cardiac high-energy phosphate metabolism alters with age as studied in 196 healthy males with the help of 31-phosphorus 2-dimensional chemical shift imaging.

Authors:  Regina Esterhammer; Gert Klug; Christian Wolf; Agnes Mayr; Sebastian Reinstadler; Hans-Josef Feistritzer; Bernhard Metzler; Michael F H Schocke
Journal:  PLoS One       Date:  2014-06-18       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.